SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Checkmate Pharmaceuticals, Inc. BuyoutNewsfile Corp • 04/20/22
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor TypesPRNewsWire • 04/19/22
Regeneron says FDA is still evaluating whether to fully approve its COVID-19 treatmentMarket Watch • 04/14/22
U.S. FDA Extends Review of Biologics License Application for REGEN-COV® (casirivimab and imdevimab) for Treatment and Prophylaxis of COVID-19PRNewsWire • 04/14/22
Regeneron (REGN), Sanofi's Dupixent Gets EU Nod for Asthma in KidsZacks Investment Research • 04/07/22
Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammationGlobeNewsWire • 04/07/22
Dupixent® (dupilumab) Approved by European Commission for Children Aged 6 to 11 Years with Severe Asthma with Type 2 InflammationPRNewsWire • 04/07/22
Regeneron Builds On Retinal Disease Expertise Via Gene Therapy Pact With ViGeneronBenzinga • 04/06/22
Regeneron to Report First Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2022PRNewsWire • 04/05/22
Press Release: FDA accepts Dupixent® (dupilumab) for Priority Review in patients aged 12 years and older with eosinophilic esophagitisGlobeNewsWire • 04/04/22
FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic EsophagitisPRNewsWire • 04/04/22